Inappropriate T-cell priming by antigen-presenting cells (APCs) and/or inadequate tumor-cell recognition via the major histocompatibility complex (MHC) may indeed serve as the Achilles’ heel in establishing robust and long-lasting tumor-immunological responses, posing challenges to overcoming immune resistance (7). The gene discussed is HLA-C; the disease is neoplasm.